Drug Type Small molecule drug |
Synonyms ITPP, Myo-inositol trispyrophosphate, OXY 111A + [2] |
Target |
Action modulators, inhibitors |
Mechanism Hemoglobins modulators, RTK inhibitors(Receptor protein-tyrosine kinase inhibitors) |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
RegulationOrphan Drug (United States) |
Molecular FormulaC6H12NaO21P6 |
InChIKeySIYCUBULEKWDSE-SUBVTSALSA-N |
CAS Registry23103-35-7 |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | Myoinositol Trispyrophosphate | - | - |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Infertility | Phase 3 | - | 01 Feb 2016 | |
| Polycystic Ovary Syndrome | Phase 3 | - | 01 Feb 2016 | |
| Bile Duct Neoplasms | Phase 2 | Switzerland | 01 Feb 2014 | |
| Colorectal Cancer | Phase 2 | Switzerland | 01 Feb 2014 | |
| Hepatocellular Carcinoma | Phase 2 | Switzerland | 01 Feb 2014 | |
| Pancreatic Cancer | Phase 2 | Switzerland | 01 Feb 2014 | |
| Heart Failure | Phase 1 | United States | - | |
| Heart Failure | Phase 1 | - | - | |
| Neoplasms | Phase 1 | United States | - | |
| Obesity | Phase 1 | - | - |
Phase 1 | 28 | qrewryotwi(onqizzbepy) = 32 treatment-related toxicities (mostly hypercalcemia) cleokgpknf (tcqqfaozij ) | Positive | 21 Jun 2021 |





